Congenital cytomegalovirus (CMV) infection causes auditory, cognitive and neurologic impairment in thousands of infants each year in the United States. Recognition of infection in pregnant women is difficult because CMV often produces few symptoms, and antiviral treatment during pregnancy may have toxic effects. Could a new experimental vaccine hold the key to preventing maternal CMV infection during pregnancy and decrease the incidence of congenital CMV infection and its sequelae? Host Dr. Jennifer Shu evaluates the progress toward a CMV vaccine with Dr. Robert Pass, professor of pediatrics and microbiology at the University of Alabama at Birmingham School of Medicine. Dr. Pass also explains the proposed mechanism of action for the vaccine.